SELECT PUBLICATIONS

Arkenau H et al. Infusional 5-f luorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. Proc ASCO 2005;Abstract 3507.

Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45. Abstract

Ellis LM. Bevacizumab. Nat Rev Drug Discov 2005;Suppl:8-9. Abstract

Ellis LM et al. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005;23(22):4853-5. No abstract available

Fernando N et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. Proc ASCO 2005;Abstract 3556.

Giantonio BJ et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presentation. ASCO GI 2005;Abstract 169a.

Hochster HS et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized “TREE-2” trial. Proc ASCO GI Cancers Symposium 2005;Abstract 241.

Hochster HS et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/ fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. Proc ASCO 2005;Abstract 3515.

Hurwitz H et al. Bevacizumab plus irinotecan, f luorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract

Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004;61(21 Suppl 5):21-6. Abstract

Kabbinavar FF et al. Addition of bevacizumab to bolus f luorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23(16):3697-705. Abstract

Kabbinavar FF et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. Proc ASCO 2004;Abstract 3516.

Kabbinavar F et al. Phase II, randomized trial comparing bevacizumab plus f luorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5. Abstract

Saltz LB et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/ irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO GI Cancers Symposium 2005;Abstract 169b.

Sastre J et al. Preliminary results of a randomized phase III trial of the TTD group comparing capecitabine and oxaliplatin (CapeOx) vs oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC). Proc ASCO 2005;Abstract 3524.

Scappaticci FA et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91(3):173-80. Abstract

Shen BQ et al. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 1999;274(46):33057-63. Abstract

Welles L et al. Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) (“Tree” study). Proc ASCO 2004;Abstract 3537.